Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution

Lung cancer is still the leading cause of both cancer-related incidence and mortality worldwide with roughly 1.8 million cases (12.9% of total) and 1.6 million deaths (19.4% of total) annually.